{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:59:24Z","timestamp":1790164764480,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40256-015-0153-0","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T17:19:43Z","timestamp":1449595183000},"page":"67-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evolocumab: A Review in Hyperlipidemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"issue":"1","key":"153_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"AL Catapano","year":"2011","unstructured":"Catapano AL, Reiner Z, De Backer G, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3\u201346.","journal-title":"Atherosclerosis."},{"issue":"25 Suppl 2","key":"153_CR2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation."},{"issue":"2","key":"153_CR3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","volume":"8","author":"GF Watts","year":"2014","unstructured":"Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8(2):148\u201372.","journal-title":"J Clin Lipidol."},{"issue":"19","key":"153_CR4","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","volume":"63","author":"AD Sniderman","year":"2014","unstructured":"Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63(19):1935\u201347.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"153_CR5","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chretien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022\u201336.","journal-title":"Circ Res."},{"key":"153_CR6","unstructured":"European Medicines Agency. Repatha (evolocumab): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 9 Nov 2015."},{"key":"153_CR7","unstructured":"Amgen Inc. Repatha\u00ae (evolocumab) injection, for subcutaneous use: US prescribing information. 2015. http:\/\/pi.amgen.com\/united_states\/repatha\/repatha_pi_hcp_english.pdf . Accessed 9 Nov 2015."},{"key":"153_CR8","unstructured":"Health Canada. Repatha (evolocumab) solution for subcutaneous injection: Canadian product monograph. 2015. http:\/\/www.hc-sc.gc.ca\/ . Accessed 9 Nov 2015."},{"issue":"7","key":"153_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1358\/dof.2013.038.07.1981967","volume":"48","author":"EA Stein","year":"2013","unstructured":"Stein EA, Wasserman SM, Dias C, et al. AMG-145. Drugs Future. 2013;48(7):451\u20139.","journal-title":"Drugs Future."},{"issue":"19","key":"153_CR10","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"CS Dias","year":"2012","unstructured":"Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888\u201398.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"153_CR11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","volume":"117","author":"DJ Blom","year":"2015","unstructured":"Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731\u201341.","journal-title":"Circ Res."},{"issue":"19","key":"153_CR12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med."},{"key":"153_CR13","unstructured":"European Medicines Agency. Repatha (evolocumab): EU assessment report. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 9 Nov 2015."},{"issue":"9","key":"153_CR14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2015.1073712","volume":"11","author":"MM Page","year":"2015","unstructured":"Page MM, Watts GF. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opin Drug Metab Toxicol. 2015;11(9):1505\u201315.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"Suppl 1","key":"153_CR15","first-page":"S69","volume":"97","author":"MG Emery","year":"2015","unstructured":"Emery MG, Gibbs JP, Slatter JG, et al. Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034]. Clin Pharmacol Ther. 2015;97(Suppl 1):S69.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl","key":"153_CR16","first-page":"1048","volume":"36","author":"E Mahlof","year":"2015","unstructured":"Mahlof E, Koren M, Emery M, et al. Relationship of body weight and dosing of evolocumab (EVO) for the treatment of hypercholesterolemia [abstract no. P5984]. Eur Heart J. 2015;36(Suppl):1048.","journal-title":"Eur Heart J."},{"issue":"20","key":"153_CR17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408\u201317.","journal-title":"Circulation."},{"issue":"9858","key":"153_CR18","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007\u201317.","journal-title":"Lancet."},{"issue":"5","key":"153_CR19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","volume":"78","author":"A Hirayama","year":"2014","unstructured":"Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073\u201382.","journal-title":"Circ J."},{"issue":"23","key":"153_CR20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497\u2013506.","journal-title":"JAMA."},{"issue":"9858","key":"153_CR21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995\u20132006.","journal-title":"Lancet."},{"issue":"9965","key":"153_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340.","journal-title":"Lancet."},{"issue":"18","key":"153_CR23","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870\u201382.","journal-title":"JAMA."},{"issue":"10 Suppl","key":"153_CR24","doi-asserted-by":"crossref","first-page":"A1369","DOI":"10.1016\/S0735-1097(15)61369-9","volume":"65","author":"A Kiyosue","year":"2015","unstructured":"Kiyosue A, Honarpour N, Xue A, et al. Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III YUKAWA 2 study [abstract no. 1107-104 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl):A1369.","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"153_CR25","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541\u20138.","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"153_CR26","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531\u201340.","journal-title":"J Am Coll Cardiol."},{"key":"153_CR27","doi-asserted-by":"crossref","unstructured":"Gibbs JP, Grover A, Emery MG, et al. Impact of target-mediated elimination on evolocumab dose and regimen [abstract no. 422]. In: European Atherosclerosis Society Annual Congress. 2015.","DOI":"10.1016\/j.atherosclerosis.2015.04.956"},{"key":"153_CR28","first-page":"A16270","volume":"130","author":"SM Wasserman","year":"2014","unstructured":"Wasserman SM, Koren MJ, Giugliano RP, et al. Evaluation of the relationship between evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens. Circulation. 2014;130:A16270.","journal-title":"Circulation."},{"key":"153_CR29","doi-asserted-by":"crossref","unstructured":"Stein EA, Koren M, Honarpour N, et al. Clinical equivalence of evolocumab 140\u00a0mg every two weeks and 420\u00a0mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies [abstract no. 1107-103]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1368.","DOI":"10.1016\/S0735-1097(15)61368-7"},{"issue":"Suppl","key":"153_CR30","first-page":"307","volume":"36","author":"E Stroes","year":"2015","unstructured":"Stroes E, Robinson J, Raal F, et al. Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies [abstract no. P1756 plus poster]. Eur Heart J. 2015;36(Suppl):307\u20138.","journal-title":"Eur Heart J."},{"key":"153_CR31","unstructured":"Amgen. A multi-center, randomized study in subjects with primary hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01849497] US National Institutes of Health, ClinicalTrials.gov. 2015. http:\/\/www.clinicaltrials.gov . Accessed 9 Nov 2015."},{"key":"153_CR32","unstructured":"Amgen. A randomized, multi-center study in subjects with hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01879319] US National Institutes of Health, ClinicalTrials.gov. 2015. http:\/\/www.clinicaltrials.gov . Accessed 9 Nov 2015."},{"issue":"16","key":"153_CR33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139.","journal-title":"N Engl J Med."},{"key":"153_CR34","doi-asserted-by":"crossref","unstructured":"Koren MJ, Giugliano R, Raal F, et al. Two year analysis of the safety and tolerability of evolocumab: the OSLER-1 study [abstract no. 914-10]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1364.","DOI":"10.1016\/S0735-1097(15)61364-X"},{"issue":"19","key":"153_CR35","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113\u201320.","journal-title":"Circulation."},{"issue":"9965","key":"153_CR36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341\u201350.","journal-title":"Lancet."},{"key":"153_CR37","first-page":"2863","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"JL Goldstein","year":"2001","unstructured":"Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 2863\u2013913.","edition":"8"},{"key":"153_CR38","doi-asserted-by":"crossref","unstructured":"Raal F, Hovingh K, Blom D, et al. Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG) study [abstract]. In: 17th International Symposium on Atherosclerosis. 2015.","DOI":"10.1016\/j.atherosclerosis.2016.07.221"},{"key":"153_CR39","doi-asserted-by":"crossref","unstructured":"Koren M, Rosenson R, Khan B, et al. LDL cholesterol reduction in elderly patients with the PCSK 9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies [abstract no. 1107-101]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1366.","DOI":"10.1016\/S0735-1097(15)61366-3"},{"issue":"10 Suppl","key":"153_CR40","doi-asserted-by":"crossref","first-page":"A1351","DOI":"10.1016\/S0735-1097(15)61351-1","volume":"65","author":"PP Toth","year":"2015","unstructured":"Toth PP, Sattar N, Genest J, et al. A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145) [abstract no. 1164\u00a0M-07 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl):A1351.","journal-title":"J Am Coll Cardiol."},{"issue":"Suppl","key":"153_CR41","first-page":"1043","volume":"36","author":"L Cho","year":"2015","unstructured":"Cho L, Dent R, Stroes E, et al. Long-term safety and efficacy of evolocumab in patients with statin intolerance [abstract no. P5968]. Eur Heart J. 2015;36(Suppl):1043.","journal-title":"Eur Heart J."},{"issue":"23","key":"153_CR42","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J."},{"issue":"13","key":"153_CR43","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","volume":"63","author":"FJ Raal","year":"2014","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278\u201388.","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"153_CR44","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","volume":"290","author":"R Romagnuolo","year":"2015","unstructured":"Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290(18):11649\u201362.","journal-title":"J Biol Chem."},{"key":"153_CR45","unstructured":"Sanofi. Praluent\u2122 (alirocumab) injection, for subcutaneous use: US prescribing information. 2015. http:\/\/products.sanofi.us\/praluent\/praluent.pdf . Accessed 9 Nov 2015."},{"key":"153_CR46","unstructured":"European Medicines Agency. Praluent (alirocumab): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 9 Nov 2015."},{"issue":"14","key":"153_CR47","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-015-0469-8","volume":"75","author":"A Markham","year":"2015","unstructured":"Markham A. Alirocumab: first global approval. Drugs. 2015;75(14):1699\u2013705.","journal-title":"Drugs."},{"issue":"1","key":"153_CR48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","volume":"163","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40\u201351.","journal-title":"Ann Intern Med."},{"key":"153_CR49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.","journal-title":"BMC Med."},{"key":"153_CR50","unstructured":"Pfizer Inc. Pfizer launches first annual PCSK9 competitive grants program to advance cardiovascular disease research. 2015. http:\/\/press.pfizer.com\/press-release\/pfizer-launches-first-annual-pcsk9-competitive-grants-program-advance-cardiovascular-d . Accessed 9 Nov 2015."},{"issue":"9965","key":"153_CR51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(14)61702-5","volume":"385","author":"RD Santos","year":"2015","unstructured":"Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet. 2015;385(9965):307\u201310.","journal-title":"Lancet."},{"key":"153_CR52","unstructured":"European Medicines Agency. Lojuxta (lomitapide): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 9 Nov 2015."},{"key":"153_CR53","unstructured":"European Medicines Agency. Kynamro (mipomersen): scientific conclusions and grounds for refusal presented by the European Medicines Agency. 2013. http:\/\/www.ema.europa.eu . Accessed 9 Nov 2015."},{"issue":"14","key":"153_CR54","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","volume":"320","author":"H Iso","year":"1989","unstructured":"Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320(14):904\u201310.","journal-title":"N Engl J Med."},{"issue":"6","key":"153_CR55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u201359.","journal-title":"N Engl J Med."},{"issue":"2","key":"153_CR56","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129(2):234\u201343.","journal-title":"Circulation."},{"key":"153_CR57","first-page":"A16865","volume":"130","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Blom D, Giugliano RP, et al. Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145). Circulation. 2014;130:A16865.","journal-title":"Circulation."},{"issue":"7","key":"153_CR58","doi-asserted-by":"crossref","first-page":"A504","DOI":"10.1016\/j.jval.2014.08.1528","volume":"17","author":"G Villa","year":"2014","unstructured":"Villa G, Schmid T, Lothgren M, et al. LDL-C lowering efficacy of evolocumab (AMG 145) could reduce apheresis in patients at high risk for cardiovascular events in Germany [abstract no. PCV183]. Value Health. 2014;17(7):A504\u20135.","journal-title":"Value Health."},{"key":"153_CR59","unstructured":"Comparative Effectiveness Public Advisory Council. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks draft report. 2015. http:\/\/cepac.icer-review.org\/wp-content\/uploads\/2015\/04\/PCSK9_Draft_Report_0908151.pdf . Accessed 9 Nov 2015."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-015-0153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-015-0153-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-015-0153-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T07:24:48Z","timestamp":1567409088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-015-0153-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1007\/s40256-015-0153-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]}}}